What is an "evolving landscape"

biopearl · Post by **biopearl** » Fri Mar 03, 2017 5:03 pm

As if Dr. Scarlett hasn't been obscure enough over the years... How is the board interpreting this language? As examples: 1. We know Jakafi failures don't live long. 2. We know Imetelstat can result in CR and PRs but we don't know if true in R/R patients. 2. We know the preliminary data in MDS mirrors the Mayo study. Are we talking about this landscape? or are we talking about 1. New drugs from other companies that are newly competitive --other JAK inhibitors, Kite like approaches, super EPO type drugs. In other words advances that have been made elsewhere that would affect J and J's commitment to the Imetelstat program. 3. Are we talking about earlier treatment to change the natural history of progression to AML from MDS? I can see this language interpreted so many different ways and would appreciate other people's about what the intended meaning is. Thanks bp